Madrigal Pharmaceuticals Inc stock is traded at $432.79, with a volume of 571,313. It is up +8.30% in the last 24 hours and down -8.26% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$399.63
Open:
$411.50
24h Volume:
571,313
Relative Volume:
0.69
Market Cap:
$10.05B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
+0.38%
1M Performance:
-8.26%
6M Performance:
-15.15%
1Y Performance:
-11.54%
1-Day Range:
$402.00$438.74
1-Week Range:
$353.54$482.73
52-Week Range:
$353.54$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS